Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc

Multiple myeloma (MM), a malignancy of mature plasma cells, remains incurable. B-cell maturation antigen (BCMA) is the lead protein target for chimeric antigen receptor (CAR) therapy because of its high expression in most MM, with limited expression in other cell types, resulting in favorable on-tar...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Neal, Julie, Cooper, Matthew L., Ritchey, Julie K., Gladney, Susan, Niswonger, Jessica, González, L. Sofía, Street, Emily, Haas, Gabriel J., Carter, Alun, Amayta, Parmeshwar N., Gao, Feng, Lee, Byung Ha, Choi, Donghoon, Berrien-Elliott, Melissa, Zhou, Alice, Fehniger, Todd A., Rettig, Mike P., DiPersio, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582278/
https://www.ncbi.nlm.nih.gov/pubmed/37399471
http://dx.doi.org/10.1182/bloodadvances.2023010032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582278/
https://www.ncbi.nlm.nih.gov/pubmed/37399471
http://dx.doi.org/10.1182/bloodadvances.2023010032

Ejemplares similares